Form 4: Sutro Biopharma CEO William Newell Reports Stock Transactions
SEC Form 4 Filing
William Newell, CEO of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- On March 1, 2024, William Newell, CEO of Sutro Biopharma, had 23,750 Restricted Stock Units (RSUs) vest.
- Following the vesting, 8,559 shares were withheld by the issuer to cover income tax obligations at a price of $4.95 per share.
- After these transactions, Newell directly owns 188,123 shares of common stock and indirectly owns 116,525 shares through the William J. Newell Family Trust DTD 03/15/2019.
- He also directly owns 71,250 derivative securities in the form of Restricted Stock Units.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and stock transactions, with no indication of positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- Shareholders are informed about the CEO's stock transactions.
- The company's financial statements will reflect the impact of stock-based compensation.
Key Dates
| Date | Description |
|---|---|
| 03/15/2019 | Date of William J. Newell Family Trust DTD |
| 03/01/2024 | Date of RSU vesting and stock transactions |
| 03/01/2027 | Expiration date of the Restricted Stock Units |
| 03/05/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.